• Latest

Eisai Receives Positive Opinion from EMA’s CHMP on Use of Antiepileptic Agent Fycompa in Pediatric Patients

Tokyo, September 23, 2020:  Eisai Co., Ltd. announced that it has received a positive opinion from the European Medicines Agency…

• New Launches

Eisai’s Fycompa for Adjunctive Treatment of Partial Onset Seizures Launched in China

New Delhi, January 07, 2019: Eisai Co., Ltd. has launched the in-house discovered and developed antiepileptic drug (AED) Fycompa, (generic…

• Archives

Eisai Submits Application in Europe Seeking Approval for Fycompa as Treatment for Pediatric Patients With Epilepsy

New Delhi, Febraury 14, 2019:  Eisai Co., Ltd. announced today that it has submitted an application to the European Medicines Agency…

Eisai’s Supplementary New Drug Application Submitted In Japan for Fycompa

As Monotherapy for Partial-Onset Seizures, Pediatric Indication for Partial-Onset Seizures, as Well as New Formulation Tokyo, February 03, 2019: Eisai Co., Ltd.…

Eisai’s New Drug Application for Perampanel Designated for Priority Review by China National Medical Products Administration

For Adjunctive Treatment of Partial Onset Seizures Tokyo, January 05, 2019: Eisai Co., Ltd. announced that its in-house discovered and…